

Guide to Quest molecular respiratory infectious disease tests

Test code	CPT code ^a	Swab specimen type & collection media ^b			Stability																									
		Anterior Nares	Nasopharyngeal	Oropharyngeal	Transport Temperature	Room Temp	Refrigerated	Frozen -20 °C	Frozen -70 °C	Adenovirus	Human Metapneumovirus	Human Parainfluenza Virus 1	Human Parainfluenza Virus 2	Human Parainfluenza Virus 3	Human Parainfluenza Virus 4	Human RSV A	Human RSV B	Influenza A	Influenza A Subtype H1	Influenza A Subtype H3	Influenza B	Rhinovirus/Enterovirus	Bocavirus	Coronavirus 229E	Coronavirus OC43	Coronavirus NL63	Coronavirus HKU1	Chlamydia pneumoniae	Mycoplasma pneumoniae	SARS-CoV-2
COVID Molecular Respiratory Pathogen Tests and Panels																														
SARS-CoV-2 RNA Qualitative NAAT (COVID-19)	39448	87635 (U0003)	UTM, UVT, VCM or 0.9% physiologic saline or Phosphate Buffered saline (PBS)	UTM, UVT, VCM or 0.9% physiologic saline or Phosphate Buffered saline (PBS)	UTM, UVT, VCM or 0.9% physiologic saline or Phosphate Buffered saline (PBS)	Frozen	5 days	5 days	Acceptable	Acceptable																				
SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT	31688	87636	UTM, UVT, VCM or 0.9% physiologic saline or Phosphate Buffered saline (PBS)	UTM, UVT, VCM, 0.9% physiologic saline or Phosphate Buffered saline (PBS)		Refrigerated (cold packs)	7 days	14 days	PBS: Unacceptable																					
SARS-CoV-2 RNA (COVID-19), Influenza A/B and RSV RNA, Qualitative NAAT	39816	0241U	VCM-GC/UTM	VCM-GC/UTM		Refrigerated (cold packs)	24 hours	7 days	Not established	Acceptable																				
SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT	31686	87633 + 87635 (U0003)		VCM-GC/UTM		Refrigerated (cold packs)	Unacceptable	5 days	Not established	Acceptable																				
SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT	31687	87633 + 87635 (U0003), 87486 (<i>C pneumoniae</i>), 87581 (<i>M pneumoniae</i>)		VCM-GPC/UTM		Refrigerated (cold packs)	Unacceptable	5 days	Not established	Acceptable																				
Molecular Respiratory Pathogen Tests and Panels (Non-COVID)																														
Influenza A or B, RNA Qualitative RT-PCR	16086	87502		M4/VCM-GC/UTM	M4/VCM-GC/UTM	Refrigerated (cold packs)	48 hours	7 days	30 days	30 days																				
Respiratory Syncytial Virus (RSV) RNA, Qualitative Real-Time PCR	16047	87634		M4, UTM/VCM or sterile saline and PBS	M4, UTM/VCM or sterile saline and PBS	Refrigerated (cold packs)	48 hours	14 days	PBS: Not acceptable	30 days	30 days																			
Influenza A and B and RSV RNA, Qualitative, Real-Time RT-PCR	91989	87631		VCM-GC		Refrigerated (cold packs)	24 hours	7 days	Unacceptable	Unacceptable																				
Respiratory Viral Panel (RVP)	95512	87633		VCM-GPC/UTM		Refrigerated (cold packs)	Unacceptable	7 days	Not established	Not established																				
Respiratory Pathogen Panel (RPP)	37444	87633, 87486 (<i>C pneumoniae</i>), 87581 (<i>M pneumoniae</i>)		VCM-GC/UTM		Refrigerated (cold packs)	Unacceptable	7 days	Not established	Not established																				

Components of panels can be ordered separately. Components available individually include Adenovirus DNA, Qualitative, Real-Time PCR (Test Code 16046); Influenza A and B Virus with Subtyping, Real-Time PCR (Test Code 91335); Parainfluenza Virus (Types 1, 2, 3 and 4) RNA, Qualitative, Real-Time PCR (Test Code 91228); Rhinovirus RNA, Real-Time PCR (Test Code 40035); Enterovirus RNA, Qualitative, Real-Time PCR (Test Code 15082); Human Metapneumovirus RNA, Qualitative, Real-Time PCR (Test Code 40034); Chlamydia pneumoniae DNA, Qualitative, Real-Time PCR (Test Code 16003); Mycoplasma pneumoniae DNA, Qualitative, Real-Time PCR (Test Code 15498).

^a The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

^b Listed are preferred specimen collection summaries; for complete information on specimen requirements, refer to the Test Directory.

PBS, Phosphate-buffered saline;
 VCM-GC, VCM green cap or equivalent;
 VCM-GPC, VCM green or purple cap or equivalent.

- The Cepheid SARS-CoV-2, Influenza A/B and RSV test, the cobas® SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests (“Tests”) have not been FDA cleared or approved.
- The Roche® test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorized is terminated or revoked sooner.
- The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests.
- The Quest test and other molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.